Masimo (MASI) Return on Equity ROE from the first quarter 2026 to first quarter 2025 and annually, average high and low, overall ranking from Apr 04 2026 to Mar 29 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Masimo Corp  (NASDAQ: MASI)

Masimo's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Masimo in the first quarter 2026?
Masimo Corp achieved a return on average equity (ROE) of 9.08 % in its first quarter 2026, which is below Masimo's average return on equity, which stands at 14.86%.

While the company's net income was fading, Masimo was able to improve its ROE compared to the fourth quarter 2025.

Within the Medical Equipment & Supplies industry 44 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 1017, from total ROE ranking in the fourth quarter 2025 at 2166.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Apr 04 2026)
I. Quarter		 (Jan 03 2026)
IV. Quarter		 (Sep 27 2025)
III. Quarter		 (Jun 28 2025)
II. Quarter		 (Mar 29 2025)
I. Quarter
Y / Y Equity Change -16.64 % -31.44 % -44.64 % -23.82 % -
Y / Y Net Income Change - - - 220.62 % -
Net Income (TTM) in Millions 76 -152 -569 -459 -494
Return On Equity (TTM) 9.08 % -17.21 % -59.14 % -40.78 % -40.95 %
MASI's Total Ranking # 1017 # 2166 # 2991 # 2184 # 2896
Equity (TTM) in Millions 789 721 810 1,043 946
Seq. Equity Change 9.39 % -10.96 % -22.32 % 10.19 % -10.03 %
Seq. Net Income Change -16.4 % - - - -

Back to MASI Management Effectiveness >> MASI's 5 Years Annual ROE >> Compare MASI ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 45
Sector # 151
Overall # 1017

Return On Equity Statistics
High Average Low
81.23 %
14.86 %
-59.14 %
(Dec 31 2016)   (Sep 27 2025)



  News about Masimo Corp Return on Equity ROE

Masimo Expands NICU Support, Enhances Clinical Trials, and Evaluates Consumer Business Separation,

IRVINE, Calif. Masimo Corporation, globally recognized for their innovative advancements in medical monitoring technologies, has announced several strategic initiatives aimed at bolstering their influence across both clinical and consumer sectors. Combined, these efforts portray a company dedicated to leveraging its technological prowess in multifarious applications, from the neonatal intensive care unit (NICU) to modern clinical trials, and even consumer-facing products. Partnership with March of Dimes: Supporting NICU FamiliesMasimo has launched a significant partnership with March of Dimes, a leading nonprofit dedicated to improving health outcomes for mothers and babies. The alliance aims to support parents navigating the challenging transition from hospital to home for babies born with complex medical needs. Statistics reveal that between 9 to 13 percent of newborns require NICU care, often due to premature birth or congenital conditions.



MASI Annual Return On Equity (Jan 03 2026)
2025		 (Dec 28 2024)
2024		 (Dec 30 2023)
2023		 (Dec 31 2022)
2022		 (Jan 01 2022)
2021
Total Equity in Millions 721 1,052 1,365 1,339 1,550
Y / Y Equity Change -31.44 % -22.93 % 1.93 % -13.63 % 10.13 %
Net Income in Millions -152 -305 82 144 230
Y / Y Net Income Change - - -43.21 % -37.51 % -4.43 %
Return On Equity -21.01 % -28.99 % 5.97 % 10.72 % 14.81 %

Back to MASI Management Effectiveness >> MASI's 5 Years Annual ROE >> Compare MASI ROE to its Competitors




More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
MASI's' Return on Equity at Yahoo Finance
MASI's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for MASI's Competitors
Subscribers only: Roe for Masimo's Suppliers
Subscribers only: Return On Equity for MASI's Customers




Companies with similar Return On Equity at Apr 04 2026, within Healthcare Sector ROE
Resmed Inc   24.76 %
Iradimed Corporation  24.48 %
Lantheus Holdings Inc   24.33 %
Prestige Consumer Healthcare Inc   24.20 %
Vertex Pharmaceuticals Inc  23.93 %
Catalyst Pharmaceuticals Inc   23.65 %
Xoma Royalty Corporation  23.64 %
Soleno Therapeutics Inc  22.85 %
Electromed Inc   22.41 %
Iqvia Holdings Inc   22.15 %
Msa Safety Inc  22.03 %
Neurocrine Biosciences Inc   21.64 %
Insulet Corporation  21.38 %
Universal Health Services Inc   21.22 %
Teva Pharmaceutical Industries Limited  20.74 %
Exagen Inc   20.63 %
Sotera Health Company  20.57 %
Puma Biotechnology Inc   20.37 %
Pediatrix Medical Group Inc   20.09 %
Ge Healthcare Technologies Inc   19.37 %
Krystal Biotech Inc   19.25 %
United Therapeutics Corporation  19.24 %
Ani Pharmaceuticals Inc  18.02 %
Inspire Medical Systems inc   17.98 %
Merck and Co Inc   17.91 %
West Pharmaceutical Services Inc   17.87 %
Strata Critical Medical Inc   17.55 %
Standard Biotools Inc   17.29 %
Harmony Biosciences Holdings inc   17.19 %
Profound Medical Corp   17.12 %

Date modified: 2026-08-30T14:50:01+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.